Congo vs Togo: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Congo
1.6%
in 2024
Togo
1.4%
in 2024
Congo rank
19th
Togo rank
20th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Congo
- Togo
How they compare
Congo currently reports 1.6% against 1.4% in Togo, a difference of 0.2%.
That makes Congo's figure about 1.1 times Togo's.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Togo ahead.
Congo ranks 19th and Togo ranks 20th of 215 countries.
Across the 2 decades both report, Congo averaged higher in 1 and Togo in 1.
Head to head by decade
| Decade | Congo | Togo | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.6% | 1.9% | 0.3% | Togo |
| 2020s | 1.6% | 1.5% | 0.1% | Congo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Congo or Togo?
- Congo, at 1.6% against 1.4% in Togo as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Congo and Togo?
- 0.2%, with Congo ahead.
- How many years of comparable data are there for Congo and Togo?
- 10 years are reported by both, from 2015 to 2024.
- How do Congo and Togo rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Congo ranks 19th and Togo ranks 20th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.